What are Chemotherapy combination with EGFR inhibitor drugs?

Chemotherapy combination with EGFR inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting EGFR (panitumumab component)). 0 are currently marketed, with 2 more in clinical development.

Chemotherapy combination with EGFR inhibitor

0 marketed 1 in Phase 3 1 in Phase 2

This page covers all Chemotherapy combination with EGFR inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting EGFR (panitumumab component), Thymidylate synthase (5-FU), EGFR (panitumumab).

Targets

EGFR (panitumumab component) · Thymidylate synthase (5-FU), EGFR (panitumumab)

Phase 3 pipeline (1)

FOLFOX/ FOLFIRI with panitumumab · Dutch Colorectal Cancer Group · Oncology
This combination uses chemotherapy (FOLFOX or FOLFIRI) to kill rapidly dividing cancer cells, while panitumumab blocks EGFR signaling to prevent tumor growth and enhance chemotherapy efficacy.

Phase 2 pipeline (1)

5-fluorouracil,leucovorin,panitumumab · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Oncology
This combination uses 5-fluorouracil and leucovorin as chemotherapy agents to inhibit thymidylate synthase and enhance fluorouracil cytotoxicity, while panitumumab blocks EGFR signaling to prevent tumor cell growth and survival.